Biograil closes €20 million to replace injections with swallowable drug device
Copenhagen's Biograil raised €20 million from Verve Ventures, Megatrend Invest and HTGF to advance its swallowable BIONDD device toward Phase 1 trials.
Topic
Biondd
Topic
Topic
Topic
Copenhagen's Biograil raised €20 million from Verve Ventures, Megatrend Invest and HTGF to advance its swallowable BIONDD device toward Phase 1 trials.